Provided by Tiger Trade Technology Pte. Ltd.

KALA BIO

0.4400
+0.041010.28%
Post-market: 0.44780.0078+1.77%19:56 EST
Volume:2.11M
Turnover:975.83K
Market Cap:12.25M
PE:-0.08
High:0.4576
Open:0.4144
Low:0.4010
Close:0.3990
52wk High:20.60
52wk Low:0.3801
Shares:27.85M
Float Shares:23.25M
Volume Ratio:2.83
T/O Rate:9.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8254
EPS(LYR):-10.1450
ROE:-708.34%
ROA:-65.81%
PB:-1.41
PE(LYR):-0.04

Loading ...

Company Profile

Company Name:
KALA BIO
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
38
Office Location:
1167 Massachusetts Avenue,Arlington,Massachusetts,United States
Zip Code:
02476
Fax:
781 642 0399
Introduction:
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Directors

Name
Position
Avi Minkowitz
Director,Chief Executive Officer and Chief Financial Officer
Andrew I. Koven
Lead Independent Director
C. Daniel Myers
Independent Director
David Lazar
Chair of the Board,Chief Operating Officer and President
Howard Rosen
Independent Director
Marjan Farid
Independent Director
Mark Iwicki
Director
Todd Bazemore
Director

Shareholders

Name
Position
Avi Minkowitz
Director,Chief Executive Officer and Chief Financial Officer
David Lazar
Chair of the Board,Chief Operating Officer and President
Darius Kharabi
Chief Business Officer
Kim Brazzell
Chief Medical Officer and Head of Research and Development